Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received a consensus recommendation of “Moderate Buy” from the seventeen analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and fourteen have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $214.5714.

Several research firms recently commented on JAZZ. Needham & Company LLC raised their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Piper Sandler reissued an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Finally, Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Barclays started research coverage of Jazz, which can raise visibility and institutional interest and is a modest positive for sentiment. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: Management presented at the TD Cowen Health Care Conference; the transcript provides updates on strategy and pipeline but did not announce major new approvals or guidance changes likely to move the stock immediately. Conference Transcript
• Neutral Sentiment: A Zacks note discusses Jazz’s reliance on international sales and how revenue mix could affect analyst forecasts — useful for modeling risk/benefit but not an immediate catalyst unless estimates are revised. Zacks International Sales Analysis
• Negative Sentiment: Large insider sale by EVP Neena M. Patil: 55,600 shares sold (~$10.65M at ~ $191.56/share), representing roughly a 49% reduction in her stake — a sizable single insider liquidation that can pressure sentiment. Neena M. Patil SEC Filing
• Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); these are meaningful percentage reductions and add to downward pressure. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing
• Negative Sentiment: CAO Patricia Carr executed multiple sales (1,253 and 1,117 shares recently), a smaller but repeated reduction that contributes to the pattern of insider selling. Patricia Carr Insider Trades

Jazz Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ JAZZ opened at $186.67 on Wednesday. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $198.00. The firm has a 50-day simple moving average of $170.40 and a two-hundred day simple moving average of $152.93. The company has a market cap of $11.49 billion, a P/E ratio of -31.27, a PEG ratio of 0.38 and a beta of 0.22. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the business posted $6.51 earnings per share. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. Research analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the sale, the senior vice president owned 28,728 shares in the company, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the transaction, the director owned 7,024 shares in the company, valued at approximately $1,348,608. This represents a 32.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 73,626 shares of company stock worth $13,979,198. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Cardinal Capital Management raised its holdings in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after purchasing an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 81 shares in the last quarter. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 81 shares in the last quarter. Tectonic Advisors LLC grew its holdings in Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after purchasing an additional 82 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its position in shares of Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.